Aclarion, Inc. ACON 深 滬
等待開盤 10-01 09:30:00 美东时间
7.65
+0.020
+0.26%
華盛通- 最 高7.78
- 今 開7.78
- 成交量 9174股
- 最 低 7.39
- 昨 收 7.63
- 總市值 445.54万
- 52周最高 3499.5105
- 市盈率 靜 --
- 換手率 1.58%
- 52周最低 6.20
- 委 比 27.67%
- 總股本 58.24万
- 歷史最高 586116.00
- 量 比 0.57
- 振 幅 5.11%
- 歷史最低 7.39
- 每 手 1
- 風險率 691.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclarion Begins Pivotal CLARITY Trial To Test Nociscan's Impact On Chronic Low Back Pain Surgeries
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the
09-25 18:05
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $22
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $20 to $22.
09-19 16:30
Aclarion taps Greg Gould as CFO
Aclarion (NASDAQ:ACON) has appointed Greg Gould as chief financial officer, effective immediately. Greg brings more than 30 years of public and private company experience, serving as CFO of Nanos Heal...
09-03 18:23
Aclarion Appoints Greg Gould as Chief Financial Officer
Aclarion, Inc. announced the appointment of Greg Gould as Chief Financial Officer (CFO) to lead the company's financial strategy and growth. Gould, with over 30 years of experience in public and private companies, replaces long-time CFO John Lorbiecki, who is retiring. Gould has a strong track record in capital raising, driving profitability, and strategic transactions. Aclarion's CEO, Brent Ness, expressed confidence in Gould's ability to enhanc...
09-03 10:00
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
08-16 03:35
Aclarion Q2 EPS $(2.75) Misses $(2.26) Estimate, Sales $19.319K Miss $30.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(2.26) by 21.68 percent. This is a 99.8 percent increase over losses of $(1.36 thousand) per share
08-15 05:44
Auddia Plans Merger With AI-Focused Thramann Holdings, Will Rebrand as New Public Tech Powerhouse
Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), today announced that in follow up to the leadership and strategic changes announced last month the Company's Board, acting upon the recommendation of
08-05 18:10
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
Aclarion, Inc. announced a 132% year-over-year increase in Nociscan scan volumes from Q2 2024 to Q2 2025, driven by new physician adoption and insurance coverage in the UK. The company achieved two consecutive quarters of growth for the first time and expects continued quarterly growth. A cost-effectiveness analysis published in a peer-reviewed journal demonstrated Nociscan's superiority over provocative discography, supporting payer coverage. Th...
08-05 10:00
Aclarion, Inc. Adjourns Annual Meeting to Solicit Votes
Aclarion, Inc. ( ($ACON) ) has shared an announcement. On July 7, 2025, Aclario...
07-08 04:51
